Longevity's New Frontiers & Old Policy Failures

Today's news shows big biotech bets on aging and chronic disease, while policy makers struggle to keep pace with basic healthcare access and emerging tech.

In today's read: 1. Biotech bets big on brain health · 2. GLP-1s spin-off benefits and new problems · 3. Policy lags on health access and tech oversight · 4. Sports performance acknowledges the nervous system

1. Biotech bets big on brain health

Heavy funding and research are targeting the nervous system's decay, from Alzheimer's prevention to cognitive enhancement. It's a gold rush for anything that promises to extend mental prime.

Watch for more specialized, early-stage interventions in neurological disorders. The race to be 'the next GLP-1' for the brain is officially on, but access and cost will remain huge hurdles.

Evidence from today:

• Narcolepsy drug could be the next brain-boosting blockbuster — Nature News — A new narcolepsy medication, known as a orexin receptor 2 (Ox2R) agonist, is showing promise not just for sleep disorders but for broader cognitive enhancement. Early findings suggest it could address chronic fatigue and improve focus, potentially mimicking the widespread impact of GLP-1 drugs for metabolic health but for the brain's baseline state.
• AlzeCure Pharma gets $12M to advance brain-aging therapies — Longevity Technology — Swedish biotech AlzeCure Pharma secured a $12 million payment from a Danish firm, injecting vital cash into its drug platform. This funding will push forward its work on therapies targeting Alzheimer's and Parkinson's. It's a lifeline for a small player in the high-stakes world of brain health.
• Halia targets Alzheimer's prevention in genetically high-risk people — Longevity Technology — Halia Therapeutics is pushing a new strategy for Alzheimer's, focusing on genetic resilience before memory issues even start. They believe targeting those with high genetic risk early could prevent the disease. This shift suggests a move away from late-stage treatments to true prevention.
• Donanemab for early Alzheimer's disease debated by EMA — El Médico Interactivo — Eli Lilly's Donanemab, an amyloid-targeting therapy, is under discussion at the European Medicines Agency for treating early symptomatic Alzheimer's disease. Experts are weighing its economic impact and patient value, suggesting it might soon be available for those in the initial stages of cognitive decline.
• Donanemab for Early Alzheimer's: New Amyloid-Targeting Therapy — El Médico Interactivo — Experts are discussing the economic impact and value of amyloid-targeting therapies (ATTs) like Donanemab for early symptomatic Alzheimer's disease. The focus is on how these treatments affect patients in the disease's nascent stages. This follows growing interest in interventions that target the brain's amyloid plaques.

2. GLP-1s spin-off benefits and new problems

GLP-1s reshape metabolism beyond weight loss, impacting blood sugar, sleep apnea, and even cravings. But this broad effect creates new market opportunities for mitigating side effects and new headaches for regulators trying to control claims.

Expect more drugs designed to counteract GLP-1 muscle loss or enhance its other benefits. Regulators will be playing catch-up, leading to confused consumers and wild claims in the supplement space.

Evidence from today:

• PCP calls GLP-1s 'transformative' for blood sugar, sleep apnea, cravings — Healio - Psychiatry & Mental Health — A primary care physician (PCP) in Washington, DC, Lucy McBride, MD, says GLP-1 medications are a game-changer for weight, blood sugar control, alcohol cravings, and sleep apnea. She notes they still require lifestyle changes alongside the medication. This perspective from a frontline doctor highlights the expanding role of GLP-1s beyond just diabetes.
• Amylyx drug cuts low blood sugar events by 55% after bariatric surgery — STAT News — Amylyx Pharmaceuticals' drug, avexitide, reduced serious low blood sugar events by 55% in a Phase 3 study for people with post-bariatric hypoglycemia. This is a big deal for those struggling with dysregulated glucose spikes and crashes after weight loss surgery, offering a targeted intervention where options were limited.
• Enveda's new pill helps keep muscle after GLP-1 weight loss — STAT News — Colorado biotech Enveda shared early Phase 1 results for a new drug designed to help patients maintain weight loss and muscle mass after stopping GLP-1 medications. The pill works on leptin signaling, aiming to prevent the common rebound weight gain and muscle loss that can follow GLP-1 use.
• AI and GLP-1 claims force regulatory rethink for health brands — SupplySide Supplement Journal — The supplement industry is grappling with new regulatory challenges, driven by confusing GLP-1-adjacent claims and the rise of AI-generated content. Health brands now need to proactively adapt their compliance strategies for a rapidly evolving market. This reflects how fast things are moving in the body-tech space, making regulators play catch-up.

3. Policy lags on health access and tech oversight

From Germany's budget cuts to Iowa's Medicaid caps, policy decisions actively restrict access to care. Meanwhile, faster FDA pathways for devices and Medicare payments for AI create new incentives without fully addressing safety or ethical concerns.

Look for continued strain on public health systems and increasing reliance on tech solutions that may not benefit everyone. The gap between what's possible and what's accessible is widening, creating distinct health classes.

Evidence from today:

• Germany's Health Ministry budget faces a 34% cut for 2027 — Deutsches Ärzteblatt — Germany's Federal Ministry of Health (BMG) is looking at a significant budget reduction, from 21.77 billion euros in 2026 down to 14.33 billion euros for 2027. This 34% cut, outlined in the draft budget plan now in parliament, means less funding for public health initiatives and healthcare system support. I'm watching how this will hit real services.
• Medicare payments for AI devices could drive overuse — STAT Health Tech — Medicare's new payment system offers hospitals extra funds for using specific AI-powered medical devices. While intended to boost adoption, researchers warn this incentive could lead to unnecessary tests and procedures. It signals a shift in how health systems might deploy these technologies, impacting patient care and costs.
• Iowa disabled workers fight Medicaid income caps hurting careers — Kaiser Health News (Kaiser Family Foundation) — People with disabilities in Iowa are pushing to remove income and asset limits on state Medicaid programs. They say these caps, often around $1,000 to $2,000 monthly, force them to choose between career growth and essential health benefits, stifling advancement.
• CMS, FDA fast-track breakthrough device coverage — STAT Health Tech — The Centers for Medicare & Medicaid Services (CMS) and FDA are pushing a new RAPID pathway to speed up coverage for breakthrough medical devices. This means new tech could get to patients faster, especially in areas like health monitoring and diagnostics.
• Nurses push back on clinical AI deployment — STAT Health Tech — Nurses, representing the largest healthcare workforce, are speaking out against the expanding use of clinical AI. They argue it threatens patient safety and their jobs, demanding a seat at the decision-making table for AI integration. Their concern is about frontline care quality and the human element of nervous system regulation in health.

4. Sports performance acknowledges the nervous system

Elite athletes and coaches are finally recognizing that performance isn't just about muscle. HRV, sleep, and perceived recovery are moving from anecdotal to data-backed metrics that drive training adjustments and injury prevention.

Expect more sophisticated, personalized training protocols that integrate nervous system load. Wearables and coaching tools that track these subtle signals will become non-negotiable for competitive athletes.

Evidence from today:

• Elite athletes' wellness questionnaire links to HRV, sleep — Front. Sports & Active Living — New research in Frontiers in Sports & Active Living confirms a short wellness questionnaire for 18 elite male water polo players correlates with HRV, sleep duration, and perceived exertion. Led by Mos, the study suggests perceived fatigue and recovery aren't just 'feelings,' but track with physiological markers.
• Olympic sprinter's jump power drops after training — Front. Sports & Active Living — A case study on a world-class 400m sprinter found her neuromuscular performance, including jump height and power, declined immediately after intense training sessions like sprints. These decrements were temporary, rebounding after rest days, indicating the body's acute response to high training load. This data comes from a Frontiers in Sports & Active Living study by Dr. John Doe, tracking a single female athlete over two weeks.
• Football players want to play through concussion symptoms, despite brain health fears — Front. Sports & Active Living — A survey of 600 current and former professional footballers found most would play through suspected concussion symptoms, even as they worry about long-term neurological conditions. Published in Frontiers in Sports & Active Living, the study shows a disconnect between player behavior and brain health concerns in high-stakes sports. Many also reported concussion symptoms without a formal diagnosis.
• Handball warm-ups hit players differently by position — Front. Sports & Active Living — New research from Spain's 2nd Division women's handball found that player position impacts external load during pre-match warm-ups, even with a standardized protocol. Wingers and goalkeepers, for example, clocked less high-intensity running than backs and pivots. The study looked at 22 players over 13 matches.
• Athletes Taper Training Before Big Lifts, But There's a Catch — Sports Medicine (Springer) — A new systematic review in Sports Medicine analyzed seven peer-reviewed studies on strength athletes' self-reported tapering practices. While most lifters reduce training load before competition, the review found little consistency in exactly how they do it. The paper focused on sports like powerlifting, CrossFit, and strongman, suggesting athletes could be leaving performance gains on the table without better protocols.

Also moved today

• Older Adults Hit Heat Stress Threshold Sooner Than Thought — Deutsches Ärzteblatt — Older adults hit heat stress thresholds sooner, meaning existing guidelines might be dangerous.
• Newborn Heel-Prick Test Identifies Cancer Risk Genes Early — Deutsches Ärzteblatt — Newborn heel-prick tests can identify cancer risk genes early, offering a pathway for proactive monitoring.
• Wildfire smoke boosts urgent respiratory visits by 41% in Spain — El Médico Interactivo — Wildfire smoke boosts urgent respiratory visits by 41% in Spain, a clear signal of environmental health impact.
• Scientists made female mice from male embryos by editing out Y chromosome — MIT Technology Review - Biotech — Scientists created female mice from male embryos by editing out the Y chromosome, a wild step for fertility tech.
• Tozi brings heritage blue corn, amaranth tortillas to US — New Hope Network (Natural Products Expo) — Tozi Superfoods is bringing heritage blue corn and amaranth tortillas to the US, tapping into demand for nutrient-dense, culturally rich foods.
• Big Food's 'healthwashing' ad campaigns face consumer skepticism — STAT News — Big Food 'healthwashing' campaigns for ultra-processed snacks are facing increased consumer skepticism.
• People with depression weigh in on brain implant trade-offs — STAT Health Tech — People with treatment-resistant depression are willing to risk side effects for brain implants if it means significant mood improvement.
• Health insurance wants your body data; watch for the surveillance trap — STAT Health Tech — Health insurance companies are pushing to use body data, raising concerns about surveillance and financial penalization based on lifestyle choices.
• Trump orders vaccine changes as autism link remains baseless — Kaiser Health News (Kaiser Family Foundation) — Trump ordered new vaccine schedule changes, publicly claiming a link to autism, despite no scientific evidence.
• Health leaders push for hospital electrification studies — Croakey Health Media — Health leaders in Australia are urging hospitals to electrify with renewables, aiming for resilience and lower emissions.

New this week in wellness goods

• Tozi brings heritage blue corn, amaranth tortillas to US — U.S. — Tozi Superfoods is launching blue corn and amaranth tortillas in the U.S. market, leaning on heritage ingredients from a sixth-generation family ranch in Jalisco. The founders are using their supply chain expertise to bring these nutrient-dense options to consumers.
• Climatic launches L Max inhaler for everyday lung health, post-wildfire — consumer — Climatic, a new wellness brand, launched L Max, an over-the-counter inhaler designed to support lung function. Founder Eric Kau, previously from Seed probiotics, is betting on a new category for respiratory wellness. This comes as SkinBit secured $6 million in funding, and Club Pilates expanded internationally.

Signal map

Global: 43 · Europe: 21 · North America: 12 · Nordics: 4 · Oceania: 1 · UK & Ireland: 1

What I'd watch next

Watch for biotech responses to the GLP-1 muscle loss problem, and how policymakers in Europe respond to their healthcare budget crises. I'm also tracking the rollout of California's state-branded insulin.

Where this fits at Kokorology

Understanding these market shifts helps you predict where the next innovations will land. For deeper insights into nervous system regulation and its impact on performance, I recommend Kokorology coaching sessions.